Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ac Immune S.A.
Industry Sector: HealthTechnology
CEO: Andrea Pfeifer, PhD
Number Of Employees: 172
Enterprise Value: $92,548,184
PE Ratio: -3.08
Exchange/Ticker 1: NASDAQ:ACIU
Exchange/Ticker 2: N/A
Latest Market Cap: $175,129,296
BioCentury | Nov 8, 2024
Product Development
The evolving picture of ARIA risk and APOE4 status in Alzheimer’s
As data on amyloid-targeting drugs have emerged, pressing questions—and answers—about their leading safety concern have come into focus
BioCentury | May 14, 2024
Politics, Policy & Law
Biosecure revised, and venture rounds, deals of note: a BioCentury podcast
What’s new in legislation seeking to rein in influence of China’s CDMOs
BioCentury | May 14, 2024
Deals
Deals Report: Sanofi-Novavax to co-commercialize Nuvaxovid, develop combination vaccines
Plus: Maze finds Pompe disease program partner in Shionogi, and updates from Takeda-AC Immune, Sanofi-Fulcrum and more
BioCentury | Jan 23, 2024
Deals
Deals roundup: Coherus sharpens oncology focus, BridgeBio bolsters balance sheet and more
BioCentury’s weekly roundup of biopharma deals, Jan. 16-22
BioCentury | Dec 16, 2023
Finance
Dec. 15 Quick Takes: Pfizer, Nona in ADC deal
Plus: FDA approves Padcev/Keytruda for 1L advanced urothelial cancer, obesity play Fractyl files for IPO and updates from Merck, Syndax, AC Immune, BMS
BioCentury | Dec 6, 2023
Management Tracks
Catalyst hires Michael Kalb as CFO
Plus: Raab to become Amicus chair when Crowley heads to BIO and updates from AC Immune, Gossamer Bio, Chimerix, Versameb, Alzheon, Kling and Avalere
BioCentury | Oct 10, 2023
Management Tracks
Amgen veteran Lenz named head of R&D at Neumora
Plus: Eaton leaving Editas as CTO, CBO and updates from Poseida, Zevra, Pheon, Lexicon and more
BioCentury | Sep 11, 2023
Guest Commentary
We must reframe the discussion on Alzheimer’s disease
We’re at a pivot point in Alzheimer’s drug development, and we mustn’t let history slow us down
BioCentury | Sep 28, 2022
Product Development
First solid win for amyloid could lead CMS to rethink controversial NCD
Full approval of Eisai’s lecanemab in Alzheimer’s could persuade CMS to re-assess requirements for class
BioCentury | Mar 22, 2022
Product Development
AC Immune clears first hurdle for α-synuclein PET tracer
With AD/PD 2022 readout, AC Immune achieves non-invasive imaging of α-synuclein in human brains with selective PET tracer
Items per page:
1 - 10 of 131